Home > Insider Trading > Filing (0001209191-21-014054)

Filing Details

Accession Number:: 0001209191-21-014054
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-24 20:31:28
Reporting Period:: 2021-02-24

Accepted Time:: 2021-02-24 20:31:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-24	358,528	$144.17	14,264,631	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	354,358	$145.04	13,910,273	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	351,112	$146.05	13,559,161	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	288,656	$147.17	13,270,505	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	267,038	$148.01	13,003,467	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	99,005	$148.91	12,904,462	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-24	35,000	$150.41	12,869,462	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,464,359	Indirect	By Flagship VentureLabs IV LLC and Flagship Pioneering, Inc.
Common Stock	2,101,703	Direct

Footnotes

These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020.
Represents 301,164 shares sold by Flagship Fund IV and 57,364 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.59 to $144.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Represents 297,660 shares sold by Flagship Fund IV and 56,698 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.59 to $145.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 294,934 shares sold by Flagship Fund IV and 56,178 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.59 to $146.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 242,471 shares sold by Flagship Fund IV and 46,185 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.59 to $147.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 224,312 shares sold by Flagship Fund IV and 42,726 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.59 to $148.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 83,164 shares sold by Flagship Fund IV and 15,841 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.59 to $149.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 29,400 shares sold by Flagship Fund IV and 5,600 shares sold by Flagship Fund IV-Rx.
Following the transactions reported herein, 8,943,918 shares are held directly by Flagship Fund IV and 3,925,544 shares are held directly by Flagship Fund IV-Rx.
11,460,435 shares are held directly by Flagship VentureLabs IV LLC ("VentureLabs IV") and 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.